Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Initial safety assessment of the endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer: NRG-GI007.
Authors
Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center, New York, NY
Geoffrey Yuyat Ku , Jennifer Moughan , Terence Marques Williams , Prasad S. Adusumilli , Makoto Nishimura , Adam Yock , Rutika Mehta , Samuel J. Klempner , Eric David Miller , Theodore S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04391049
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 341)
DOI
10.1200/JCO.2024.42.3_suppl.341
Abstract #
341
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E.
First Author: Takako Yoshii
Poster
2022 ASCO Annual Meeting
GOTIC-018: Phase I, open-label, multicenter study to assess the safety of pre- and co-administration of ONO-4538 (nivolumab) with concurrent chemoradiation (CCRT) in patients (pts) with locally advanced cervical carcinoma (LACvCa).
First Author: Akira Yabuno
Poster
2022 ASCO Annual Meeting
Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.
First Author: Ana Oaknin
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz